Dominant Intermediate Charcot-Marie-Tooth disorder is not due to a catalytic defect in tyrosyl-tRNA synthetase - PubMed (original) (raw)
. 2011 Aug 23;50(33):7132-45.
doi: 10.1021/bi200989h. Epub 2011 Jul 26.
Affiliations
- PMID: 21732632
- DOI: 10.1021/bi200989h
Dominant Intermediate Charcot-Marie-Tooth disorder is not due to a catalytic defect in tyrosyl-tRNA synthetase
Clifford A Froelich et al. Biochemistry. 2011.
Abstract
Charcot-Marie-Tooth disorder (CMT) is the most common inherited peripheral neuropathy, afflicting 1 in every 2500 Americans. One form of this disease, Dominant Intermediate Charcot-Marie-Tooth disorder type C (DI-CMTC), is due to mutation of the gene encoding the cytoplasmic tyrosyl-tRNA synthetase (TyrRS). Three different TyrRS variants have been found to give rise to DI-CMTC: replacing glycine at position 41 by arginine (G41R), replacing glutamic acid at position 196 by lysine (E196K), and deleting amino acids 153-156 (Δ(153-156)). To test the hypothesis that DI-CMTC is due to a defect in the ability of tyrosyl-tRNA synthetase to catalyze the aminoacylation of tRNA(Tyr), we have expressed each of these variants as recombinant proteins and used single turnover kinetics to characterize their abilities to catalyze the activation of tyrosine and its subsequent transfer to the 3' end of tRNA(Tyr). Two of the variants, G41R and Δ(153-156), display a substantial decrease in their ability to bind tyrosine (>100-fold). In contrast, the E196K substitution does not significantly affect the kinetics for formation of the tyrosyl-adenylate intermediate and actually increases the rate at which the tyrosyl moiety is transferred to tRNA(Tyr). The observation that the E196K substitution does not decrease the rate of catalysis indicates that DI-CMTC is not due to a catalytic defect in tyrosyl-tRNA synthetase.
© 2011 American Chemical Society
Similar articles
- Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy.
Jordanova A, Irobi J, Thomas FP, Van Dijck P, Meerschaert K, Dewil M, Dierick I, Jacobs A, De Vriendt E, Guergueltcheva V, Rao CV, Tournev I, Gondim FA, D'Hooghe M, Van Gerwen V, Callaerts P, Van Den Bosch L, Timmermans JP, Robberecht W, Gettemans J, Thevelein JM, De Jonghe P, Kremensky I, Timmerman V. Jordanova A, et al. Nat Genet. 2006 Feb;38(2):197-202. doi: 10.1038/ng1727. Epub 2006 Jan 22. Nat Genet. 2006. PMID: 16429158 - Drosophila as a platform to predict the pathogenicity of novel aminoacyl-tRNA synthetase mutations in CMT.
Leitão-Gonçalves R, Ermanoska B, Jacobs A, De Vriendt E, Timmerman V, Lupski JR, Callaerts P, Jordanova A. Leitão-Gonçalves R, et al. Amino Acids. 2012 May;42(5):1661-8. doi: 10.1007/s00726-011-0868-4. Epub 2011 Mar 8. Amino Acids. 2012. PMID: 21384131 - Boosting BDNF in muscle rescues impaired axonal transport in a mouse model of DI-CMTC peripheral neuropathy.
Rhymes ER, Simkin RL, Qu J, Villarroel-Campos D, Surana S, Tong Y, Shapiro R, Burgess RW, Yang XL, Schiavo G, Sleigh JN. Rhymes ER, et al. Neurobiol Dis. 2024 Jun 1;195:106501. doi: 10.1016/j.nbd.2024.106501. Epub 2024 Apr 6. Neurobiol Dis. 2024. PMID: 38583640 - Spectrophotometric assays for monitoring tRNA aminoacylation and aminoacyl-tRNA hydrolysis reactions.
First EA, Richardson CJ. First EA, et al. Methods. 2017 Jan 15;113:3-12. doi: 10.1016/j.ymeth.2016.10.010. Epub 2016 Oct 22. Methods. 2017. PMID: 27780756 Review. - Evolution of the tRNA(Tyr)/TyrRS aminoacylation systems.
Bonnefond L, Giegé R, Rudinger-Thirion J. Bonnefond L, et al. Biochimie. 2005 Sep-Oct;87(9-10):873-83. doi: 10.1016/j.biochi.2005.03.008. Epub 2005 Apr 8. Biochimie. 2005. PMID: 16164994 Review.
Cited by
- Boosting BDNF in muscle rescues impaired axonal transport in a mouse model of DI-CMTC peripheral neuropathy.
Rhymes ER, Simkin RL, Qu J, Villarroel-Campos D, Surana S, Tong Y, Shapiro R, Burgess RW, Yang XL, Schiavo G, Sleigh JN. Rhymes ER, et al. bioRxiv [Preprint]. 2024 Mar 11:2023.04.09.536152. doi: 10.1101/2023.04.09.536152. bioRxiv. 2024. PMID: 38559020 Free PMC article. Updated. Preprint. - Knockdown of SIRT2 Rescues YARS-induced Charcot-Marie-Tooth Neuropathy in Drosophila.
Li X, Wang M, Gao X, Li C, Chen C, Qi Y, Wan Y, Yu W. Li X, et al. Neurosci Bull. 2024 Apr;40(4):539-543. doi: 10.1007/s12264-023-01156-0. Epub 2023 Dec 8. Neurosci Bull. 2024. PMID: 38066253 No abstract available. - Dominant aminoacyl-tRNA synthetase disorders: lessons learned from in vivo disease models.
Kalotay E, Klugmann M, Housley GD, Fröhlich D. Kalotay E, et al. Front Neurosci. 2023 May 12;17:1182845. doi: 10.3389/fnins.2023.1182845. eCollection 2023. Front Neurosci. 2023. PMID: 37274211 Free PMC article. Review. - Aminoacyl-tRNA synthetases in human health and disease.
Turvey AK, Horvath GA, Cavalcanti ARO. Turvey AK, et al. Front Physiol. 2022 Oct 18;13:1029218. doi: 10.3389/fphys.2022.1029218. eCollection 2022. Front Physiol. 2022. PMID: 36330207 Free PMC article. Review. - Histidine supplementation can escalate or rescue HARS deficiency in a Charcot-Marie-Tooth disease model.
Qiu Y, Kenana R, Beharry A, Wilhelm SDP, Hsu SY, Siu VM, Duennwald M, Heinemann IU. Qiu Y, et al. Hum Mol Genet. 2023 Feb 19;32(5):810-824. doi: 10.1093/hmg/ddac239. Hum Mol Genet. 2023. PMID: 36164730 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical